Molecular Cancer Therapeutics CTRC-AACR San Antonio Breast Cancer Symposium
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ikeda, N.
Right arrow Articles by Kubota, Y.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ikeda, N.
Right arrow Articles by Kubota, Y.
Vol. 2, 739-746, August 2003     Molecular Cancer Therapeutics
© 2003 American Association for Cancer Research

Combination Treatment with 1{alpha},25-Dihydroxyvitamin D3 and 9-cis-Retinoic Acid Directly Inhibits Human Telomerase Reverse Transcriptase Transcription in Prostate Cancer Cells

Naoya Ikeda, Hiroji Uemura1, Hitoshi Ishiguro, Mayumi Hori, Masahiko Hosaka, Satoru Kyo, Ken-ichi Miyamoto, Eiji Takeda and Yoshinobu Kubota

Department of Urology, Graduate School of Medicine, Yokohama City University, Kanagawa 236-0004, Japan [N. I., H. U., H. I., M. Hos., Y. K.]; Department of Oral Pathology, Kanagawa Dental College, Kanagawa 238-8580, Japan [M. Hor.]; Department of Obstetrics and Gynecology, School of Medicine, Kanazawa University, Ishikawa 920-8641, Japan [S. K.]; and Departments of Nutritional Science [K-i. M.] and Clinical Nutrition [E. T.], School of Medicine, Tokushima University, Tokushima 770-8503, Japan

1 To whom requests for reprints should be addressed, at Department of Urology, School of Medicine, Yokohama City University, Fukuura 3-9, Kanazawa-ku, Yokohama, Kanagawa 236-0004, Japan. E-mail: hu0428{at}med.yokohama-cu.ac.jp

The vitamin D3 receptor, which is the nuclear receptor for 1{alpha},25-dihydroxyvitamin D3 (VD3), forms a heterodimer with the retinoid X receptor (RXR), which is the nuclear receptor for 9-cis-retinoic acid (9-cis-RA). The heterodimer binds to a specific response element consisting of two directly repeated pairs of motifs, AGGTGA, spaced by three nucleotides [direct repeat (DR) 3] and modulates the expression of VD3-responsive genes. Telomerase activity, which is seen in most immortal cells and germ cells, is a complex of enzymes that maintain the length of telomeres. One of the major components of human telomerase, human telomerase reverse transcriptase (hTERT), is the catalytic subunit, and the expression of hTERT might correlate most strongly with telomerase activity. We found that the sequence of 5'-AGTTCATGGAGTTCA-3' (DR3') is similar to that of DR3 in the promoter region of hTERT. Our results showed that the combination of VD3 and 9-cis-RA inhibited telomerase activity through direct interaction of the heterodimer of vitamin D3 receptor and RXR with the DR3' sequence in the hTERT promoter as well as the combination of VD3 and selective RXR ligand did. Also, in vivo data showed that the growth of xenografts in nude mice was inhibited by VD3 and 9-cis-RA. The results of the present study provide evidence on the molecular mechanism of the inhibition of cell growth by these agents, and they could be novel therapeutic agents for prostate cancer.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2003 by the American Association for Cancer Research.